Syndicate content

Archive - Feb 27, 2013


Cancer “Vaccine” Shows Promise of Treating and Preventing Metastatic Cancers

Preclinical, laboratory studies suggest that a novel immunotherapy could potentially work like a vaccine against metastatic cancers, according to scientists at Virginia Commonwealth University (VCU) Massey Cancer Center. Results from a recent study show the therapy could treat metastatic cancers and be used in combination with current cancer therapies while helping to prevent the development of new metastatic tumors and train specialized immune system cells to guard against cancer relapse. First published online on January 18, 2013 in the journal Cancer Research, the study detailed the effects of a molecule engineered by lead author Xiang-Yang Wang, Ph.D., on animal and cell models of melanoma, prostate, and colon tumors. The molecule called Flagrp-170 consists of two distinct proteins, glucose-regulated protein 170 (Grp170), known as a "molecular chaperone," and a "danger signal" derived from flagellin, a protein commonly found in bacteria. The researchers used modified viruses, or adenoviruses, that can no longer replicate to transport Flagrp-170 directly to the tumor site to achieve localized vaccination. The novel therapy caused a profound immune response that significantly prolonged survival in animal models. "Successfully promoting antitumor immunity will help eradicate tumor cells, control cancer progression, and help prevent tumor relapse," says Dr. Wang, Harrison Scholar, member of the Cancer Molecular Genetics research program at the VCU Massey Cancer Center and associate professor of Human and Molecular Genetics at the VCU School of Medicine.

Fungal Defense Compound May Lead to Anti-Cancer Drugs

Inspired by a chemical that fungi secrete to defend their territory, MIT chemists have synthesized and tested several dozen compounds that may hold promise as potential anti-cancer drugs. A few years ago, MIT researchers, led by associate professor of chemistry Dr. Mohammad Movassaghi, became the first to chemically synthesize 11,11'-dideoxyverticillin, a highly complex fungal compound that has shown anti-cancer activity in previous studies. This and related compounds naturally occur in such small amounts that it has been difficult to do a comprehensive study of the relationship between the compound's structure and its activity, research that could aid drug development, Dr. Movassaghi says. "There's a lot of data out there, very exciting data, but one thing we were interested in doing is taking a large panel of these compounds, and for the first time, evaluating them in a uniform manner," Dr. Movassaghi says. In the new study, published online on January 24, 2013 in the journal Chemical Science, Dr. Movassaghi and colleagues at MIT and the University of Illinois at Urbana-Champaign (UIUC) designed and tested 60 compounds for their ability to kill human cancer cells. "What was particularly exciting to us was to see, across various cancer cell lines, that some of them are quite potent," Dr. Movassaghi says. The lead author of the paper is MIT postdoc Dr. Nicolas Boyer. Other authors are MIT graduate student Justin Kim, UIUC chemistry professor Dr. Paul Hergenrother and UIUC graduate student Karen Morrison. Many of the compounds tested in this study, known as epipolythiodiketopiperazine (ETP) alkaloids, are naturally produced by fungi. Scientists believe these compounds help fungi prevent other organisms from encroaching on their territory.